Heyholder

This is an amended filing · View original →

‹ Back to the disclosure you were reading

SAMSUNG BIOLOGICS CO.,LTD. PolyPeptide tender offer ends at 97.98% tendered, squeeze-out of remaining shares planned

SAMSUNG BIOLOGICS CO.,LTD.· Material Event ReportAmended

AI summary · Not investment advice

SAMSUNG BIOLOGICS CO.,LTD.'s tender offer for PolyPeptide Group AG, decided in July, ended with 97.98% (32,350,302 shares) tendered; it plans to acquire the remaining shares through a squeeze-out and other means.

Acquisition amount

KRW 2.7 trillion

36.32% of equity; based on a tender price of CHF 44.31 per share; actual amount may vary with the tender result and exchange rate

Key facts

Counterparty
Draupnir Holding B.V. and tendering shareholders · AmendedThe issuer's largest shareholder, Draupnir Holding B.V., committed to tender all 18,375,000 shares (55.65%); restated from 'Draupnir Holding B.V. and other tendering shareholders'
Purpose of transaction
Strengthen business competitiveness by acquiring a peptide CDMO company
Issuer
PolyPeptide Group AGSwitzerland; peptide CDMO
Stake after transaction
100%33,016,411 shares owned; may vary with the tender result
% of equity
36.32%2025 year-end consolidated
Payment terms
Paid in cash within 10 trading days after the offer ends and merger approval, funded by a rights offering etc. · AmendedCash on hand to be used if funding changes
External valuation opinion
Value per share estimated at CHF 31.43 to CHF 63.22; no grounds found to judge the price of CHF 44.31 per share inappropriate · AmendedDeloitte Anjin LLC; evaluated 2026.07.14 ~ 2026.07.17
Board resolution date
Jul 17, 2026

Commentary

AI commentary · Not investment advice

What happened

Samsung Biologics has completed its tender offer (an offer to buy shares from all shareholders at a set price during a set period) for PolyPeptide Group AG of Switzerland. Shares tendered reached 97.98% (32,350,302 shares). It plans to obtain the remaining shares through a squeeze-out under Swiss law and other means, to own 100%. This correction adds that result and restates the counterparties as Draupnir Holding B.V. and tendering shareholders. PolyPeptide is a peptide CDMO (a company that develops and makes drugs for other firms). Its largest shareholder, Draupnir Holding B.V., had agreed to tender all 18,375,000 shares it held (55.65%). The plan set in July was to buy 33,016,411 shares for KRW 2.7 trillion. The tender price is CHF 44.31 per share. These figures assume the maximum number of shares available, excluding treasury shares. The actual amount may change with the tender result and exchange rate.

In the company's terms

On a 2025 year-end consolidated basis, the amount equals 36.32% of Samsung Biologics' equity and 24.47% of its total assets. An outside accounting firm, Deloitte Anjin LLC, valued the shares at CHF 31.43 to CHF 63.22 each. It said it found no grounds to judge the purchase price inappropriate.

What changes for shareholders

Payment will be in cash. It is due within 10 trading days after the offer period ends and merger approval is received. Funds will come from a paid-in capital increase (selling new shares to raise money) and other sources. Cash on hand will be used if plans change. The planned share transfer date is December 31, 2026. It may change depending on approvals.

Earlier Material Event Report filings from this company

Filings of the same type
FiledTitleKey figure · Note
22.01.28[Amended] Material Event Report2,270,000 shares

Comments

No comments yet

Comments from shareholders will appear here.